Cargando…

Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice

Cancer cells have acquired several pathways to escape from host immunity in the tumor microenvironment. Programmed death 1 (PD-1) receptor and its ligand PD-L1 are involved in the key pathway of tumor immune escape, and immune checkpoint therapy targeting PD-1 and PD-L1 has been approved for the tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuruta, Akito, Shiiba, Yuki, Matsunaga, Naoya, Fujimoto, Marina, Yoshida, Yuya, Koyanagi, Satoru, Ohdo, Shigehiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Tumor Microenvironment and Immunobiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381128/ https://www.ncbi.nlm.nih.gov/pubmed/35190830 http://dx.doi.org/10.1158/1541-7786.MCR-21-0786

Ejemplares similares

BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
por: Bady, Elena, et al.
Publicado: (2023)

Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD‐1 antibodies
por: Levingston, Corinne A., et al.
Publicado: (2017)

JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer
por: Cioni, Bianca, et al.
Publicado: (2023)

Mechanical Stress Signaling in Pancreatic Cancer Cells Triggers p38 MAPK- and JNK-Dependent Cytoskeleton Remodeling and Promotes Cell Migration via Rac1/cdc42/Myosin II
por: Kalli, Maria, et al.
Publicado: (2022)

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics
por: Siefert, Joseph C., et al.
Publicado: (2021)

T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62
por: Daniel, Colin J., et al.
Publicado: (2022)

Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors
por: Khlebus, Eleonora, et al.
Publicado: (2023)

The identification of TCF1(+) progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade
por: Tabanelli, Valentina, et al.
Publicado: (2022)

Cancer‐associated fibroblasts promote PD‐L1 expression in mice cancer cells via secreting CXCL5
por: Li, Ziqian, et al.
Publicado: (2019)

Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD‐1 receptor
por: Tumino, Nicola, et al.
Publicado: (2019)

A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma
por: Kim, Sang‐Soo, et al.
Publicado: (2019)

Challenges of PD-L1 testing in non-small cell lung cancer and beyond
por: Wang, Minyu, et al.
Publicado: (2020)

RNA editing enzyme ADAR1 governs the circadian expression of P-glycoprotein in human renal cells by regulating alternative splicing of the ABCB1 gene
por: Omata, Yuji, et al.
Publicado: (2021)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

RNA editing enzyme ADAR1 controls miR-381-3p-mediated expression of multidrug resistance protein MRP4 via regulation of circRNA in human renal cells
por: Omata, Yuji, et al.
Publicado: (2022)

P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma
por: Seifert, Nicole, et al.
Publicado: (2022)

Transient receptor potential ankyrin 1 (TRPA1) plays a critical role in a mouse model of cancer pain
por: Antoniazzi, Caren Tatiane De David, et al.
Publicado: (2018)

The IL‐1/IL‐1R axis induces greater fibroblast‐derived chemokine release in human papillomavirus‐negative compared to positive oropharyngeal cancer
por: Al‐Sahaf, Sarmad, et al.
Publicado: (2018)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

High frequency of CD4(+)FoxP3(+) cells in HTLV-1 infection: inverse correlation with HTLV-1–specific CTL response
por: Toulza, Frederic, et al.
Publicado: (2008)

The immunosuppression pathway of tumor‐associated macrophages is controlled by heme oxygenase‐1 in glioblastoma patients
por: Magri, Sara, et al.
Publicado: (2022)

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export
por: Chen, Fang-Fang, et al.
Publicado: (2020)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression
por: Lv, Tingting, et al.
Publicado: (2022)

Transcriptional profiling of breast cancer‐associated lymphatic vessels reveals VCAM‐1 as regulator of lymphatic invasion and permeability
por: Dieterich, Lothar C., et al.
Publicado: (2019)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

The host genomic environment of the provirus determines the abundance of HTLV-1–infected T-cell clones
por: Gillet, Nicolas A., et al.
Publicado: (2011)

Ovarian cancer‐associated mesothelial cells induce acquired platinum‐resistance in peritoneal metastasis via the FN1/Akt signaling pathway
por: Yoshihara, Masato, et al.
Publicado: (2020)

SATB1 dictates expression of multiple genes including IL-5 involved in human T helper cell differentiation
por: Ahlfors, Helena, et al.
Publicado: (2010)

Circadian clock component PERIOD2 regulates diurnal expression of Na(+)/H(+) exchanger regulatory factor-1 and its scaffolding function
por: Tsurudome, Yuya, et al.
Publicado: (2018)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

T028: Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
por: Paczkowska, Julia, et al.
Publicado: (2022)

Diurnal expression of MRP4 in bone marrow cells underlies the dosing-time dependent changes in the oxaliplatin-induced myelotoxicity
por: Kato, Mizuki, et al.
Publicado: (2020)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Kortekaas, Kim E, et al.
Publicado: (2021)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
por: Schoenfeld, A.J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p4vr0i4f5svfjeacsrg03np0c7